FibroBiologics, Inc. (FBLG) Key Metrics
FBLG valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.9M
- Enterprise value
- $7.2M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 2.0 10-yr median 7.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.74
FBLG key metrics, FY2021–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsFBLG valuation Price multiples at each fiscal year-end price.
FBLG returns How much profit the business earns on the capital it uses.
FBLG per-share figures Results divided by the shares outstanding at year-end.
FBLG financial health Debt, liquidity and how easily interest is covered.
FBLG efficiency & capital use Working capital cycle and where the cash goes.
FBLG valuation history
FBLG returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
FBLG debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
FBLG price vs earnings per share
FBLG key metrics
FY2021–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $2.1M | $20.5M | $162.1M | — | — | — |
| Enterprise value | −$367,762 | $17.0M | $154.7M | — | — | — |
| Price / book | 0.3 | 7.5 | 129.4 | — | — | — |
| Earnings yield | −881.1% | −54.6% | −10.2% | — | — | — |
| Free cash flow yield | −787.1% | −59.1% | −4.3% | — | — | — |
| Share price at fiscal year-end | $0.95 | $12.44 | $99.80 | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$8.35 | −$6.79 | −$10.15 | −$3.15 | −$0.97 | −$0.72 |
| Operating cash flow per share | −$7.34 | −$7.24 | −$3.94 | −$2.50 | −$0.87 | −$0.72 |
| Free cash flow per share | −$7.46 | −$7.35 | −$4.24 | −$2.50 | −$0.87 | −$0.72 |
| Cash per share | $2.19 | $8.51 | $5.64 | $1.40 | $0.25 | — |
| Book value per share | $2.76 | $1.66 | $0.77 | −$2.46 | −$0.79 | — |
| Tangible book value per share | $2.76 | $1.66 | $0.77 | −$2.46 | −$0.79 | — |
| Capex per share | $0.12 | $0.11 | $0.30 | $0.00 | $0.00 | $0.00 |
| Debt per share | $1.08 | $6.42 | $1.08 | $4.63 | $0.80 | — |
| Shares outstanding | 2.2M | 1.6M | 1.6M | 1.6M | 1.6M | 1.6M |
| Change in shares outstanding | +35.8% | +1.2% | +0.0% | 0.0% | −0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −419.4% | −559.7% | — | — | — | — |
| Return on invested capital (ROIC) | −884.2% | — | — | −815.9% | — | — |
| Return on assets (ROA) | −143.1% | −79.0% | −198.1% | −193.5% | −338.0% | — |
| Return on tangible assets | −193.8% | −67.9% | −139.5% | −106.2% | −338.0% | — |
| Financial health | ||||||
| Total debt | $2.4M | $10.6M | $1.7M | $7.5M | $1.3M | — |
| Cash & short-term investments | $4.9M | $14.0M | $9.2M | $2.3M | $407,000 | — |
| Net debt | −$2.5M | −$3.4M | −$7.4M | $5.3M | $893,000 | — |
| Debt / equity | 0.39 | 3.86 | 1.39 | — | — | — |
| Debt / assets | 0.25 | 0.64 | 0.15 | 1.56 | 2.78 | — |
| Current ratio | 3.61 | 1.12 | 1.00 | 0.37 | 0.27 | — |
| Quick ratio | 3.61 | 1.12 | 1.00 | 0.37 | 0.27 | — |
| Interest coverage | -81.6 | -686.9 | -60.5 | -6.8 | -394.5 | — |
| Working capital | $4.6M | $1.5M | $32,000 | −$4.4M | −$1.3M | — |
| Invested capital | $3.7M | −$697,000 | −$6.2M | $1.3M | −$397,000 | — |
| Tangible asset value | $6.2M | $2.7M | $1.3M | −$4.0M | −$1.3M | — |
| Net current asset value | $2.9M | $518,000 | −$1.4M | −$6.2M | −$1.3M | — |
| Graham net-net per share | $0.64 | $0.17 | −$0.86 | −$3.90 | −$0.83 | — |
| Capital allocation | ||||||
| Capex / depreciation | 0.31 | 0.32 | 1.13 | 0.00 | — | 0.00 |
| Efficiency | ||||||
| Days payables outstanding | 798.9 | 1,318.9 | 919.6 | 1,924.0 | — | — |
| Receivables turnover | — | — | — | 0.00 | — | — |
| Payables turnover | 0.46 | 0.28 | 0.40 | 0.19 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Average receivables | — | — | — | $300,000 | — | — |
| Average payables | $1.8M | $2.1M | $1.1M | $495,500 | $233,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Computed from FBLG's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
FBLG valuation and financial ratios
FibroBiologics earned a return on equity of −419.4% and a return on invested capital of −884.2% in fiscal 2026. It ended the year with $2.4 million of debt and $4.9 million in cash and short-term investments, a net cash position of $2.5 million. The share count rose 37.5% from 1.6M to 2.2M over 5 years.
See the FBLG income statement, the FBLG chart for price history, or the FBLG stock overview for the latest quote and news.
FBLG key metrics FAQ
What is FibroBiologics's return on equity?
FibroBiologics's return on equity (ROE) was −419.4% in fiscal 2026: net income of -$18.6 million on average shareholders' equity of $4.4 million.
What is FibroBiologics's ROIC?
FibroBiologics's return on invested capital was −884.2% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does FibroBiologics have?
FibroBiologics had total debt of $2.4 million at the end of fiscal 2026, a debt-to-equity ratio of 0.39 and more cash than debt.
What is FibroBiologics's free cash flow yield?
FibroBiologics generated -$16.7 million of free cash flow in fiscal 2026, a free cash flow yield of −787.1% on its market value at year-end ($2.1 million).
What is FibroBiologics's current ratio?
FibroBiologics's current ratio was 3.61 at the end of fiscal 2026: current assets were 3.61 times current liabilities.